Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (41-50 of 209) with videos related to

Pageof 21
Sort By:
The Journal of Urology|October 9, 2012
Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinomaSunil Saroha, Robert G Uzzo, Elizabeth R Plimack, et al.
European Urology Oncology|July 7, 2019
Effect of Immunotherapy on Local Treatment of Genitourinary MalignanciesGéraldine Pignot, Yohann Loriot, Ashish M Kamat, et al.
Therapeutic Advances in Urology|December 2, 2015
Muscle-invasive urothelial bladder cancer: an update on systemic therapyHayley Knollman, J Luke Godwin, Rishi Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. AdesunloyeElizabeth R Plimack, Jean Hoffman-Censits, Jonathan E Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Reply to S. Buti and S. CulineYu-Ning Wong, Elizabeth R Plimack, Samuel Litwin, et al.
The Oncologist|July 13, 2013
AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumorsElizabeth R Plimack, Patricia M Lorusso, Patricia McCoon, et al.
JAMA Oncology|June 17, 2016
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder CarcinomaDavid Liu, Elizabeth R Plimack, Jean Hoffman-Censits, et al.
European Urology Oncology|May 19, 2019
Role of Checkpoint Inhibition in Localized Bladder CancerNoah M Hahn, Andrea Necchi, Yohann Loriot, et al.
Urologic Oncology|July 5, 2022
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitorsBenjamin Miron, Elizabeth Handorf, Kevin Zarrabi, et al.
Clinical Genitourinary Cancer|October 10, 2024
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of CyclesAnumita Chakraborty, Jill Hasler, Elizabeth Handorf, et al.
Pageof 21

Showing results (41-50 of 209) with videos related to

Sort By:
Pageof 21
The Journal of Urology|October 9, 2012
Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinomaSunil Saroha, Robert G Uzzo, Elizabeth R Plimack, et al.
European Urology Oncology|July 7, 2019
Effect of Immunotherapy on Local Treatment of Genitourinary MalignanciesGéraldine Pignot, Yohann Loriot, Ashish M Kamat, et al.
Therapeutic Advances in Urology|December 2, 2015
Muscle-invasive urothelial bladder cancer: an update on systemic therapyHayley Knollman, J Luke Godwin, Rishi Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. AdesunloyeElizabeth R Plimack, Jean Hoffman-Censits, Jonathan E Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Reply to S. Buti and S. CulineYu-Ning Wong, Elizabeth R Plimack, Samuel Litwin, et al.
The Oncologist|July 13, 2013
AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumorsElizabeth R Plimack, Patricia M Lorusso, Patricia McCoon, et al.
JAMA Oncology|June 17, 2016
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder CarcinomaDavid Liu, Elizabeth R Plimack, Jean Hoffman-Censits, et al.
European Urology Oncology|May 19, 2019
Role of Checkpoint Inhibition in Localized Bladder CancerNoah M Hahn, Andrea Necchi, Yohann Loriot, et al.
Urologic Oncology|July 5, 2022
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitorsBenjamin Miron, Elizabeth Handorf, Kevin Zarrabi, et al.
Clinical Genitourinary Cancer|October 10, 2024
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of CyclesAnumita Chakraborty, Jill Hasler, Elizabeth Handorf, et al.
Pageof 21